Kiniksa Pharmaceuticals International (KNSA) Profit After Tax (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Profit After Tax for 10 consecutive years, with $25.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax rose 41.73% year-over-year to $25.4 million; the trailing twelve-month figure through Jun 2026 stood at $80.8 million (up 1590.13% YoY), and the FY2025 full-year result was $59.1 million, up 236.39% from the prior year.
• Profit After Tax rose to $25.4 million in Q2 2026 per KNSA's latest filing, from $22.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at $224.1 million in Q3 2022 and bottomed at -$25.2 million in Q1 2022.
• Historically, Profit After Tax has averaged $14.5 million across 5 years, with a median of $6.6 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax jumped 832.01% in 2022, then sank 135.64% in 2024.
• Over 5 years, Profit After Tax stood at $4.6 million in 2022, then surged by 453.1% to $25.3 million in 2023, then tumbled by 135.64% to -$9.0 million in 2024, then jumped by 259.03% to $14.3 million in 2025, then surged by 77.49% to $25.4 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $25.4 million, $22.6 million, and $14.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.